Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Maxpro Ventures is a biomedical technology investment firm founded in 2013 and based in Taipei, Taiwan. The firm manages a portfolio of 34 companies and invests globally across the healthcare sector, from early-stage startups to late-stage multinational corporations.
Maxpro Ventures targets breakthrough biomedical technology companies, focusing on next-generation cell and gene therapies, biologic drugs, medical devices, diagnostics, and healthcare services. Investment stages range from pre-seed to growth equity, with check sizes varying based on the company's development stage.
Notable companies in Maxpro Ventures' portfolio include ABC-KY, Advaxis, AngenMed, and JHL Biotech.
Email your pitch deck to BP@maxproventures.com for consideration.
Yes, Maxpro Ventures often leads investment rounds, particularly in early-stage companies within their focus sectors.
The firm is open to follow-on investments, especially for companies that demonstrate significant progress and alignment with their investment thesis.
Specific fund size details are not disclosed, but the firm actively manages a diverse portfolio of 34 companies.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.